BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38219610)

  • 1. The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer.
    Nie X; Xu T; Zhang L; Cheng W
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():97-104. PubMed ID: 38219610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram.
    Li H; Cai S; Deng L; Xiao Z; Guo Q; Qiang J; Gong J; Gu Y; Liu Z
    Eur Radiol; 2023 Aug; 33(8):5298-5308. PubMed ID: 36995415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram].
    Mao MM; Li HM; Shi J; Qiu QS; Feng F
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(3):201-208. PubMed ID: 35042289
    [No Abstract]   [Full Text] [Related]  

  • 4. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
    Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
    Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing precision medicine: a nomogram for predicting platinum resistance in epithelial ovarian cancer.
    Li R; Xiong Z; Ma Y; Li Y; Yang Y; Ma S; Ha C
    World J Surg Oncol; 2024 Mar; 22(1):81. PubMed ID: 38509620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
    Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
    Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and Validation of a Nomogram to Predict the Postoperative Venous Thromboembolism Risk in Patients with HGSOC.
    Huang Z; Li L; Gong Z; Tang L
    Clin Appl Thromb Hemost; 2024; 30():10760296241255958. PubMed ID: 38767088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram of Combining CT-Based Body Composition Analyses and Prognostic Inflammation Score: Prediction of Survival in Advanced Epithelial Ovarian Cancer Patients.
    Wang X; Zhang C; Cao F; Wang CB; Dong JN; Wang ZH
    Acad Radiol; 2022 Sep; 29(9):1394-1403. PubMed ID: 34955366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study.
    Yin R; Guo Y; Wang Y; Zhang Q; Dou Z; Wang Y; Qi L; Chen Y; Zhang C; Li H; Jian X; Ma W
    Acad Radiol; 2023 Sep; 30 Suppl 2():S192-S201. PubMed ID: 37336707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
    Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
    [No Abstract]   [Full Text] [Related]  

  • 18. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
    Marchocki Z; Tone A; Virtanen C; de Borja R; Clarke B; Brown T; May T
    J Ovarian Res; 2022 May; 15(1):50. PubMed ID: 35501919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors affecting long-term survival of advanced high-grade serous ovarian cancer].
    Shen YM; Jin LQ; Tang SS; Wang Y; Lyu WG; Chen ZB; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):393-400. PubMed ID: 34154314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.